Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$506.6 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Acquires Testosterone Treatment Nebido\u2122 From Bayer","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Grunenthal","pharmaFlowCategory":"D","amount":"$498.1 million","upfrontCash":"Undisclosed","newsHeadline":"Gr\u00fcnenthal Closes Deal To Acquire Testosterone Therapy Nebido\u2122 From Bayer For \u20ac495 Million","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Bayer AG"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Jardiance\u00ae (empagliflozin) Approved in the EU for the Treatment of Adults with Chronic kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","amount":"$28.3 million","upfrontCash":"$28.3 million","newsHeadline":"Lupin Acquires Brands ONDERO\u00ae and ONDERO MET\u00ae to Expand Diabetes Portfolio in India","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Approves Jardiance\u00ae for the Treatment of Adults with Chronic Kidney Disease","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Boehringer Ingelheim GmbH"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter
    ×
    FILTER:
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size
            filter Upfront Payment

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Product Type

              Companies

              Boehringer Ingelheim GmbH

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              US FDA Approves Jardiance® for the Treatment of Adults with Chronic Kidney Disease

              Details:

              Jardiance® (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

              Lead Product(s): Empagliflozin

              Therapeutic Area: Endocrinology Product Name: Jardiance

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Boehringer Ingelheim GmbH

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lupin Acquires Brands ONDERO® and ONDERO MET® to Expand Diabetes Portfolio in India

              Details:

              Through the acquisition, Lupin expands its diabetes portfolio in India by gaining access to Ondero (linagliptin) and Ondero Met (linagliptin & metformin). Ondero is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes.

              Lead Product(s): Linagliptin

              Therapeutic Area: Endocrinology Product Name: Ondero

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Lupin Ltd

              Deal Size: $28.3 million Upfront Cash: $28.3 million

              Deal Type: Acquisition August 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Boehringer Ingelheim GmbH

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Jardiance® (empagliflozin) Approved in the EU for the Treatment of Adults with Chronic kidney Disease

              Details:

              Jardiance (empagliflozin) is an inhibitor of SGLT2. By inhibiting SGLT2, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion for chronic kidney disease.

              Lead Product(s): Empagliflozin

              Therapeutic Area: Endocrinology Product Name: Jardiance

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 25, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bayer AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Grünenthal Closes Deal To Acquire Testosterone Therapy Nebido™ From Bayer For €495 Million

              Details:

              Nebido (having testosterone undecanoate) is the only available injectable long-acting depot preparation of testosterone undecanoate, developed for the treatment of male hypogonadism.

              Lead Product(s): Testosterone Undecanoate

              Therapeutic Area: Endocrinology Product Name: Nebido

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Grunenthal

              Deal Size: $498.1 million Upfront Cash: Undisclosed

              Deal Type: Acquisition November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Bayer AG

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Grünenthal Acquires Testosterone Treatment Nebido™ From Bayer

              Details:

              Nebido (testosterone undecanoate) is used for male hypogonadism. It is used for treating clinical symptoms such as regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido or erectile dysfunction due to low testosterone levels.

              Lead Product(s): Testosterone Undecanoate

              Therapeutic Area: Endocrinology Product Name: Nebido

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Grunenthal

              Deal Size: $506.6 million Upfront Cash: Undisclosed

              Deal Type: Acquisition July 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY